title: Type 2 diabetes: genotype-based therapy.
abstract: Targeting a genetic variant with an antagonist may restore insulin secretion in a subgroup of type 2 diabetes patients (Tang et al., this issue).
authors.affiliation: Department of Molecular Medicine and Surgery, Karolinska Institutet, Karolinska University Hospital, SE-17176, Stockholm, Sweden. claes-goran.ostenson@ki.se.
authors.forename: Claes-Goran
authors.initials: CG
authors.lastname: Ostenson
mesh_terms: D058669:Adrenergic alpha-2 Receptor Antagonists / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000235:genetics*; D005260:Female; D006801:Humans; D008297:Male; D018341:Receptors, Adrenergic, alpha-2 / Q000235:genetics*
chemical_list: C547768:ADRA2A protein, human; D058669:Adrenergic alpha-2 Receptor Antagonists; D018341:Receptors, Adrenergic, alpha-2